| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 115,565 | 44,006 | ||
| Short-term investments | 175,319 | 229,273 | ||
| Prepaid expenses and other current assets | 5,758 | 5,324 | ||
| Total current assets | 296,642 | 278,603 | ||
| Property and equipment, net | 50 | 61 | ||
| Operating lease right-of-use assets, net | 807 | 1,010 | ||
| Long-term investments | 10,717 | 1,614 | ||
| Other non-current assets | 13,802 | 11,797 | ||
| Total assets | 322,018 | 293,085 | ||
| Accounts payable | 6,444 | 7,931 | ||
| Accrued expenses | 45,359 | 44,520 | ||
| Operating lease liabilities, current | 618 | 793 | ||
| Total current liabilities | 52,421 | 53,244 | ||
| Royalty obligation | 72,989 | - | ||
| Operating lease liabilities, less current portion | 180 | 215 | ||
| Total long-term liabilities | 73,169 | - | ||
| Total liabilities | 125,590 | 53,459 | ||
| Common stock, par value 0.0001 per share 175,000,000 shares authorized 42,213,465 and 41,793,412 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 4 | 4 | ||
| Additional paid-in capital | 721,179 | 712,903 | ||
| Accumulated other comprehensive (loss) income | -69 | -94 | ||
| Accumulated deficit | -524,686 | -473,187 | ||
| Total stockholders' equity | 196,428 | 239,626 | ||
| Total liabilities and stockholders' equity | 322,018 | 293,085 | ||
Zenas BioPharma, Inc. (ZBIO)
Zenas BioPharma, Inc. (ZBIO)